{"entity":{"id":"nct05804045","kind":"trial","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","aka":[],"tldr":"A phase 3 trial of Pimicotinib(ABSK021) in tenosynovial giant cell tumour, run by Abbisko Therapeutics Co, Ltd, active and no longer recruiting.","summary":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) is a phase 3 interventional study registered as NCT05804045 by Abbisko Therapeutics Co, Ltd, with 94 participants enrolled, started 2023-04-27 and due to reach its primary completion in 2024-09-23. Interventions recorded: Pimicotinib(ABSK021) and Placebo. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05804045","url":"https://clinicaltrials.gov/study/NCT05804045"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tenosynovial-giant-cell-tumour"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05804045","phase":"3","setting":"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor","sponsor":"Abbisko Therapeutics Co, Ltd","enrolled":94,"outcomes":[]},"route":"/trials/nct05804045/","neighbours":{"cancer":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}]}}